Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Star Therapeutics in the transaction. Star Therapeutics announced its oversubscribed $90 million Series C financing to continue growth of its...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented U.S. Venture Partners on the deal. U.S. Venture Partners (USVP) announced the formation of its $400 million fund, U.S. Venture Partners XIII. USVP partners with...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented Ancora Biotech on the deal. Ancora Biotech, a California-based biotechnology company, announced its $60 million Series A financing co-led by Lightspeed Venture Partners and...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Electra Therapeutics on the deal. Electra Therapeutics, a clinical-stage biotechnology company, announced its $84 million Series B financing co-led...
You must be a Standard 1 Year member to access this content.
Goldman Sachs & Co. acted as financial advisor to Amgen and Latham & Watkins as its legal advisor. Gunderson Dettmer Stough Villeneuve Franklin & Hachigian and...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP advised Amgen Inc on the deal. Amgen Inc (NASDAQ:AMGN) announced its acquisition of Rodeo Therapeutics. Amgen is one of...
You must be a Standard 1 Year member to access this content.
